According to an editorial, the differences between the overall survival and progression free survival may well be due to differences in the pace of progression before the start of treatment, which may have affected the results as there was no defined specific time period in which progression should have occurred before patients entered the study. Furthermore, only the group with short history of disease showed a significant increase in overall survival. In light of these limitations, the authors note the phase 3 ANNOUNCE study (NCT02451943) with doxorubicin plus olaratumab or placebo, which is currently recruiting, has overall survival as the primary endpoint suggesting that because of the higher number of patients, the result will be more powerful than this study.